TABRECTA 200 mg/1 (Capmatinib TABLET, FILM COATED) 200 mg/1

TABRECTA 200 mg is a film-coated tablet used for targeted therapy. It contains capmatinib, a medication often discussed in cancer treatment protocols. Learn more about its uses and effects.

Strength

200 mg/1

Pack Size

56 TABLET, FILM COATED in 1 BOTTLE (0078-0716-94)

Manufacturer / TM Owner

Novartis Pharmaceuticals Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TABRECTA 200 mg is primarily used in targeted therapy for certain types of cancer. Capmatinib, the active ingredient, is designed to interact with specific proteins involved in cancer cell growth. Patients and healthcare providers often explore what TABRECTA is used for in managing advanced or metastatic cancers.

Side Effects

Common effects of TABRECTA 200 mg may include gastrointestinal issues, fatigue, and skin reactions. Some users report mild to moderate side effects, which can vary based on individual health conditions. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

TABRECTA 200 mg should be handled with care, following the guidance of a healthcare professional. It is important to store the medication properly and adhere to prescribed usage. Patients with pre-existing conditions should discuss potential risks with their doctor.

Avoid Interactions

TABRECTA 200 mg may interact with certain medications, including those metabolized by the liver. Alcohol and other substances can also affect its efficacy. Always inform your healthcare provider about all medications and supplements you are taking.

Frequently Asked Questions

TABRECTA 200 mg is used in targeted therapy for certain types of cancer, often involving specific protein interactions.

TABRECTA 200 mg is taken orally, typically as directed by a healthcare provider. Always follow their instructions for proper administration.

Common side effects may include gastrointestinal issues, fatigue, and skin reactions. Individual experiences can vary.

TABRECTA 200 mg may interact with certain medications. Always consult a healthcare provider before combining it with other drugs.

TABRECTA 200 mg may be available from licensed online pharmacies. Ensure you purchase from a reputable source.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.